GLPG 1690
At the end of the summer (likely in September), the company will give an update on enrollment in the phase 3 ISABELA trials and should also be able to forecast when it will be able to give the futility analysis of the trial. So far, the trial is going well, though it is the first phase 3 trial the company will be running on its own and is of wide scope; there are 230 sites globally.

Whereas data was shown at EULAR for nintedanib in treating pulmonary function decline associated with systemic sclerosis, GLPG is trialing GLPG 1690 in treating the underlying disease itself (NOVESA phase 2 trial). The trial is small, and GLPG believes there is still a lot to learn in terms of what endpoints the FDA views as important in this indication and should learn more as other assets proceed through the regulatory process.